NCT00049374 2019-10-17
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 2 Completed
Clinical Trials
26 trialsNCT00047229 2017-11-08
Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
University Health Network, Toronto
Phase 2 Completed
NCT00054639 2014-05-28
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00016263 2014-01-06
Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00017589 2014-01-06
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00017602 2014-01-06
Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00024440 2014-01-06
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00059813 2013-08-26
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003103 2013-07-03
Chemotherapy in Treating Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00049192 2013-06-04
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00062244 2013-06-04
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00079131 2013-06-04
Oblimersen in Treating Patients With Merkel Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00054548 2013-05-16
Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00004870 2013-02-21
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 1/2 Completed
NCT00005032 2013-02-11
Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
University of Chicago
Phase 1/2 Completed
NCT00004862 2013-02-01
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00017251 2013-01-24
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00086944 2013-01-24
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00039481 2013-01-17
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00042978 2013-01-14
Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00085228 2012-09-24
Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00055822 2012-07-04
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 1/2 Completed
NCT00636545 2012-04-06
Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors
Genta Incorporated
Phase 1 Completed
NCT00518895 2011-11-07
AGENDA
Genta Incorporated
Phase 3 Completed
NCT00070083 2009-04-07
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00543231 2007-10-12
A Phase I Study of G3139 Subcutaneous in Solid Tumors
Genta Incorporated
Phase 1 Completed